Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma

Summary

RATIONALE: Monoclonal antibodies such as epratuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase III trial to determine the effectiveness of epratuzumab in treating patients who have low-grade non-Hodgkin's lymphoma that has not responded to chemotherapy or rituximab.

Timeline

Start

2001-09

Primary completion

—

Completion

—

Drugs

Indications